{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:10:12Z","timestamp":1794712212205,"version":"4.9.1"},"reference-count":47,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>CPX-351 was approved for the treatment of acute myeloid leukemia (AML) using now-outdated definitions of AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML. We evaluated whether the overall survival (OS) benefit of CPX-351 over standard cytarabine plus anthracycline (7+3) therapy is confined to molecularly defined AML subgroups by performing DNA sequencing in 184 patients enrolled in the pivotal phase 3 randomized trial. Patients were categorized hierarchically based on gene mutations: (1) TP53-AML, (2) DDX41-AML, (3) myelodysplasia-related AML (AML-MR) defined by the World Health Organization fifth edition criteria, or (4) other-AML. TP53-AML was subclassified as single (TP53single) or multihit (TP53multi) based on the number of alleles altered via mutation, deletion, or copy neutral loss of heterozygosity. Two-year OS differed significantly across molecular subgroups: TP53-AML (7%), AML-MR (19%), other-AML (37%), and DDX41-AML (70%) (P&amp;lt; .001). CPX-351 improved survival in patients with AML-MR compared with 7+3 (median, 9.7 vs 6.8 months; P = .037), with no benefit in TP53-AML or other-AML. For patients undergoing transplantation, CPX-351 improved 2-year survival (76% vs 27%; P&amp;lt; .01), an effect primarily observed in AML-MR. Multivariable analysis confirmed the independent association with survival of both CPX-351 and hematopoietic cell transplantation in AML-MR. TP53multi demonstrated significantly worse survival than TP53single (median, 3.8 vs 7.0 months; P = .004). The OS benefit of CPX-351 observed in the trial was driven by AML-MR with no benefit of CPX-351 in TP53-AML, in which the primary prognostic factor was allelic state. This trial was registered at www.clinicaltrials.gov as #NCT01696084.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019378","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:12:03Z","timestamp":1770063123000},"page":"2854-2864","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"first","affiliation":[{"name":"1Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Leukemia Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-8968","authenticated-orcid":false,"given":"H. Moses","family":"Murdock","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Keating","sequence":"additional","affiliation":[{"name":"3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison K.","family":"Tsai","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7095-6740","authenticated-orcid":false,"given":"Archana","family":"Sasi","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Gibson","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"5Jazz Pharmaceuticals, PLC, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Wagner","sequence":"additional","affiliation":[{"name":"5Jazz Pharmaceuticals, PLC, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalina","family":"Dronamraju","sequence":"additional","affiliation":[{"name":"5Jazz Pharmaceuticals, PLC, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-6449","authenticated-orcid":false,"given":"Tara L.","family":"Lin","sequence":"additional","affiliation":[{"name":"6Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Prebet","sequence":"additional","affiliation":[{"name":"7Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"8Georgia Cancer Center, Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-0996","authenticated-orcid":false,"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[{"name":"9Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Lancet","sequence":"additional","affiliation":[{"name":"10Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9551-7533","authenticated-orcid":false,"given":"Christopher R.","family":"Reilly","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"3Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"2Leukemia Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-806X","authenticated-orcid":false,"given":"R. Coleman","family":"Lindsley","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"26","key":"2026042811212689700_bib1","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026042811212689700_bib2","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"issue":"9","key":"2026042811212689700_bib3","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2026042811212689700_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026042811212689700_bib5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2026042811212689700_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2026042811212689700_bib7","article-title":"Phase II, multicenter, randomized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreated AML 60-75 years of age","author":"Lancet","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2026042811212689700_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2026042811212689700_bib9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","article-title":"Inherited and somatic defects in DDX41 in myeloid neoplasms","volume":"27","author":"Polprasert","year":"2015","journal-title":"Cancer Cell"},{"issue":"8","key":"2026042811212689700_bib10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2015-10-676098","article-title":"Novel germ line DDX41 mutations define families with a lower age of MDS\/AML onset and lymphoid malignancies","volume":"127","author":"Lewinsohn","year":"2016","journal-title":"Blood"},{"key":"2026042811212689700_bib11","article-title":"Germline DDX41 mutations define a unique subtype of myeloid neoplasms","author":"Makishima","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026042811212689700_bib12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2021015328","article-title":"Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study","volume":"140","author":"Duployez","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026042811212689700_bib13","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/ajh.27070","article-title":"Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants","volume":"98","author":"Bataller","year":"2023","journal-title":"Am J Hematol"},{"issue":"6","key":"2026042811212689700_bib14","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"7540","key":"2026042811212689700_bib15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"5","key":"2026042811212689700_bib16","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis","volume":"19","author":"Christiansen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026042811212689700_bib17","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2026042811212689700_bib18","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41375-024-02230-w","article-title":"Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"2026042811212689700_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.19105","article-title":"Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients","volume":"204","author":"Nanaa","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"2026042811212689700_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-024-01000-2","article-title":"Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"14","author":"Badar","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"2026042811212689700_bib21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"2026042811212689700_bib22","author":"Swerdlow","year":"2008"},{"key":"2026042811212689700_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021014520","article-title":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients","author":"Murdock","year":"2022","journal-title":"Blood"},{"key":"2026042811212689700_bib24","first-page":"JCO2300866","article-title":"Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant Clinical Trials Network 1102 Study","author":"Versluis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026042811212689700_bib25","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"2026042811212689700_bib26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"14","key":"2026042811212689700_bib27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood.2023020209","article-title":"Prevalence and significance of DDX41 gene variants in the general population","volume":"142","author":"Cheloor Kovilakam","year":"2023","journal-title":"Blood"},{"issue":"14","key":"2026042811212689700_bib28","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1182\/bloodadvances.2022007613","article-title":"Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes","volume":"6","author":"Tsai","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2026042811212689700_bib29","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jmoldx.2020.06.006","article-title":"Targeted informatics for optimal detection, characterization, and quantification of FLT3 internal tandem duplications across multiple next-generation sequencing platforms","volume":"22","author":"Tsai","year":"2020","journal-title":"J Mol Diagn"},{"issue":"4","key":"2026042811212689700_bib30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"345","key":"2026042811212689700_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/01621459.1974.10480131","article-title":"Evaluation of response-time data involving transient states: an illustration using heart-transplant data","volume":"69","author":"Mantel","year":"1974","journal-title":"J Am Stat Assoc"},{"issue":"23","key":"2026042811212689700_bib32","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2026042811212689700_bib33","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomised comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 Trial","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2026042811212689700_bib34","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026042811212689700_bib35","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1200\/JCO.2010.34.2873","article-title":"Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation","volume":"29","author":"Chen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026042811212689700_bib36","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"key":"2026042811212689700_bib37","article-title":"Long-term real world evidence of CPX-351 of high-risk AML patients identified high rate of negative MRD and prolonged OS","author":"Cluzeau","year":"2024","journal-title":"Blood Adv"},{"issue":"17","key":"2026042811212689700_bib38","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1182\/bloodadvances.2021006468","article-title":"Transplant outcomes after CPX-351 vs 7+3 in older adults with newly diagnosed high-risk and\/or secondary AML","volume":"6","author":"Uy","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2026042811212689700_bib39","first-page":"3533","article-title":"Prognostic impact of \u201cmulti-hit\u201d versus \u201csingle-hit\u201d TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases","volume":"109","author":"Badar","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"2026042811212689700_bib40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41375-021-01404-0","article-title":"AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome","volume":"36","author":"Li","year":"2022","journal-title":"Leukemia"},{"issue":"17","key":"2026042811212689700_bib41","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood.2019000909","article-title":"Germline DDX41 mutations define a significant entity within adult MDS\/AML patients","volume":"134","author":"S\u00e9bert","year":"2019","journal-title":"Blood"},{"key":"2026042811212689700_bib42","article-title":"Trial eligibility, treatment patterns and outcome for venetoclax-based therapy in AML: a prospective cohort study","author":"Wolach","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2026042811212689700_bib43","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(23)00273-9","article-title":"10-day decitabine versus 3+7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial","volume":"10","author":"L\u00fcbbert","year":"2023","journal-title":"Lancet Haematol"},{"issue":"13","key":"2026042811212689700_bib44","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2026042811212689700_bib45","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41375-024-02175-0","article-title":"Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"key":"2026042811212689700_bib46","article-title":"Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML","author":"Lu","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026042811212689700_bib47","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/blood-2022-162525","article-title":"A phase 2 randomized study comparing venetoclax and azacitidine to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia","volume":"140","author":"Fathi","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/8\/2854\/2515382\/blooda_adv-2025-019378-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/8\/2854\/2515382\/blooda_adv-2025-019378-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:21:36Z","timestamp":1777389696000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/8\/2854\/566388\/CPX-351-selectively-benefits-patients-with-AML-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019378","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,28]]},"published":{"date-parts":[[2026,4,28]]}}}